Insilico study of COVID-19 ORF1ab protein allergenicity
F. Hajighasemi (Tehran, Islamic Republic of Iran), A. Shirkavand (Tehran, Islamic Republic of Iran)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Hajighasemi (Tehran, Islamic Republic of Iran), A. Shirkavand (Tehran, Islamic Republic of Iran). Insilico study of COVID-19 ORF1ab protein allergenicity. 3211
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|